Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
ID07541911

A Study to Evaluate the Performance of En-face Fluorescence Confocal Microscopy (LaserSAFE) for Margin Analysis During Radical Prostatectomy

Led by University College, London · Updated on 2026-05-18

693

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a new technique called LaserSAFE to detect cancer at the edges of the prostate during surgery for prostate cancer. The study focuses on whether LaserSAFE can help surgeons decide if it is safe to preserve the nerves around the prostate, especially in patients usually not considered for nerve-sparing surgery. The study also examines how quickly and reliably LaserSAFE provides this information during the operation. The LaserSAFE technique uses a special fluorescence confocal microscope to scan the removed prostate tissue in the operating room within about five minutes. The prostate is prepared by cleaning, staining with a special solution, rinsing, and then scanned on both sides. Trained pathologists interpret the images to identify any cancer at the surgical margins and communicate results during surgery. If cancer is detected beyond certain limits, additional tissue including nerves may be removed. Participants will complete quality of life questionnaires before surgery and at 3 and 12 months after. They will undergo standard robot-assisted prostate surgery with nerve-sparing attempted initially, with LaserSAFE guiding any further tissue removal. Routine follow-up visits will be part of standard care. Researchers will measure outcomes including the accuracy of LaserSAFE in detecting positive margins, cancer rates after surgery, urinary incontinence, and erectile function over 12 months.

CONDITIONS

Brief Title

A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with clinically significant operable cT2-T3a N0 M0 prostate cancer.
  • Medically fit to undergo robot-assisted radical prostatectomy.
  • Scheduled for robot-assisted prostate surgery with recommendation against nerve sparing on at least one side based on clinical and imaging assessments.
  • Able to read English and give informed consent.
Not Eligible

You will not qualify if you...

  • Patients who received neo-adjuvant androgen deprivation therapy.
  • MRI indicates very low likelihood of cancer spread near nerves (EPE Likert 1 score or tumor away from posterolateral prostate areas).
  • MRI indicates high likelihood of cancer spread near nerves (Likert 5 score or bulging tumor on MRI T2 images).
  • Preoperative imaging shows rectal involvement or seminal vesicle invasion where nerve sparing is unsafe.
  • Patients previously treated for prostate cancer with radiotherapy, brachytherapy, focal therapy, or chemotherapy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Day of surgery

Participants undergo confocal microscopy imaging during their radical prostatectomy to assess surgical margins in real-time.

1 visit (in-person, during surgery)

Long-term Monitoring

Duration - 12 months

Participants are monitored for up to 12 months after surgery to assess clinical outcomes such as positive margin rates, biochemical failure, and functional scores.

Follow-up visits as per routine clinical care

Trial Site Locations

Total: 1 location

1

University College London Hospital NHS Foundation Trust

London, United Kingdom, NW1 2BU

Actively Recruiting

Loading map...

Research Team

R

Ricardo Almeida-Magana, Dr

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

0

Similar Trials

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With...

Prostate Cancer

Actively Recruiting

1 location

A Phase 1b Study of 177Lu-PSMA-617 Combined With Liver Direc...

Metastatic Prostate Cancer

Actively Recruiting

1 location

18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Phase III Ac...

Prostate Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here